

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) Sökande APREA AB, Stockholm SE
Applicant (s)

(21) Patentansökningsnummer 0300812-5 ✓
Patent application number

(86) Ingivningsdatum 2003-03-24 ✓
Date of filing

REC'D	14 APR 2004
WIPO	PCT

Stockholm, 2004-03-26

För Patent- och registreringsverket
For the Patent- and Registration Office

Marita Öun

Marita Öun

Avgift
Fee

PRIORITY
DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

46 8 4291070

Ink. t. Patent- och reg.verket

2003-03-24

Huvudfakten Kessan

USE OF CHEMICAL COMPOUNDS FOR PREPARING PHARMACEUTICAL COMPOSITIONS, AND A METHOD OF TESTING SUBSTANCES FOR MEDICAL EFFECT**5 Field of the invention**

The present invention relates to the use of certain compounds, capable of transferring wild type p53 from an inactive and non-functional conformation into its active conformation, for the preparation of a pharmaceutical composition for use in treating medical conditions wherein wt p53 exists in an inactive state defined herein, and especially malignant melanoma. The invention also relates to a method of testing of compounds for the above-mentioned ability, wherein the level of inactive wt p53 is monitored. The method can be carried out both *in vitro* and *in vivo*.

15 Background art


Although the tumour suppressor protein p53 is mutated in most human tumours, wild type (wt) p53 is dominant in malignant melanoma (Hollstein et al., *Science*, 253: 49-53, (1991); Sparrow et al., *Melanoma Res.* 1995, 5: 93-100 (1995); Hartmann et al., *Int J cancer*, 67: 313-317, (1996); and Petitclerc et al., *Cancer Res.*, 59: 2724-2730 (1999)), found Mab LM609, a function-blocking monoclonal antibody directed to $\alpha_v\beta_3$ integrin, to block M21 melanoma growth by inducing tumour apoptosis.

25 Malignant melanoma are typically refractory to apoptosis induction by chemical drugs or radioactivity.

Summary of invention

30 The present inventors have found certain compounds to be capable of inducing apoptosis in malignant melanoma cells, which compounds are defined in claim 1 as having a structure according to the formula I

46 8 4291070



2

Ink. t Patent- och reg.verket

2003-03-24

Huvudfakten Klasser

wherein:

- 5 R_1 and R_2 are independently selected from hydrogen, hydroxymethyl, or
a methylene group linked to the nitrogen atom of an amine-substituted phenyl
group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine,
or benzimidazol residue, or R_1 and R_2 may together represent a double bonded me-
thylene group, and;

- 10 A_1 and A_2 are independently selected from hydrogen, hydroxyl, and
benzoyloxy, or A_1 and A_2 may together represent an oxygen atom being double
bonded, with the proviso that when either of A_1 and A_2 is a benzoyloxy group, both
 R_1 and R_2 are hydrogen.

- 15 Same compounds are also believed to be capable of inducing apoptosis in angio-
genic vascular cells during angiogenesis, thereby inducing regression of angiogenic
blood vessels and blocking various disease states dependent on blood vessel forma-
tion and/or vascular cell survival, including the growth and metastasis of various
human tumours; adult blindness, e.g. caused by diabetic retinopathy or macular
degeneration; psoriasis; states of chronic inflammation, e.g. rheumatoid arthritis;
20 and hemangioma.

The present inventors have also found a previously unknown and most unexpected
inactive conformation state of wt p53 protein. The inactive wt p53 conformation has
now been found in malignant melanoma cells. More importantly, said inactive wt
25 p53 conformation can be reverted into a functional active conformation, capable of
inducing apoptosis. Based on these findings, the present invention, in another as-
pect, provides a method of testing substances for their ability in transforming inac-
tive wt p53 conformation into an active wt p53 conformation, and thus for finding
suitable substances for treating malignant melanoma. The method is defined in
30 claim 7. Since same inactive wt p53 conformation also is believed to be present in
angiogenic vascular cells during angiogenesis, same substances are also thought to

46 8 4291070

2003-03-24

Huvudfoxen Kassan

3

be useful in inhibiting angiogenesis in pathological conditions known to involve angiogenesis.

Brief description of the attached drawings

5

FIGURE 1A shows the percentage of apoptotic cells as function of time in human melanoma cells M21 expressing integrin $\alpha_v\beta_3$ and M21L lacking integrin $\alpha_v\beta_3$.

FIGURE 1B shows the percentage of apoptotic cells as function of time in human melanoma cells M0, lacking integrin $\alpha_v\beta_3$; M0-2baV, M0 cells overexpressing a

10 chimer of the extracellular domain of the integrin IIb subunit with the cytoplasmic tail of the integrin α_V subunit; and M0- α_V cells expressing high levels of the integrin α_V subunit.

FIGURE 1C illustrates the cell surface expression of integrin $\alpha_v\beta_3$ and the integrin β_3 subunit in different human melanoma cell lines.

15 FIGURE 1D shows the results of an analysis for cleavage of caspase-8 and caspase-9.

FIGURE 2A; upper panel depicts the specific p53 DNA binding activity in M21 and M21L cells collected from 3D-collagen using an electrophoretic gel shift assay (EMSA) with a p53 supershift using Pab 421; Lower panel presents the protein levels of p53 as compared to actin as a loading control.

20 FIGURE 2B, same as figure 2A upper panel, but with M0 and M0av cells.

FIGURE 2C shows acetylation of p53 at lysine 382.

Data shown in FIGURE 2D represents Pab 1620 and Pab 240 reactivity as percentage of D01 reactivity (total p53) in M21 ($\alpha_v\beta_3+$) cells and M21L ($\alpha_v\beta_3-$) cells.

25 FIGURE 3A shows the percentage of apoptotic cells in M21 cells ($\alpha_v\beta_3+$), M21L cells ($\alpha_v\beta_3-$) and a number of clones of M21L cells ($\alpha_v\beta_3-$) stably transfected with a dominant negative p53-His175, including M21Lp53His175-0, M21Lp53His175-1, M21Lp53His175-8 and M21Lp53His175-32.

FIGURE 3B illustrates tumour growth *in vivo* of cells used in Figure 3A.

30 FIGURE 3C the graph displays values of mean tumour volumes over time out of 5-7 animals for each tumour cell type shown in the Figure.

FIGURE 3D depicts a scatter graph showing the distribution of tumour wet weights after 25 d of tumour growth in mice of M21, M21L, M21Lp53His175-0 and M21Lp53His175-8.

2003-03-24

Huvudfaxen Kassan

4

FIGURE 4A shows the results of examination of p53 conformation with Pab1620 and Pab240 in melanoma cells incubated with or without 100 µM of PRIMA-1 for 5d.

In FIGURE 4B the results of analysis of apoptosis in M21 and M21L cells in 3D-collagen with or without PRIMA-1 treatment for 5 d are shown.

FIGURE 4C shows mean tumour volumes over time of M21 human melanoma cells grown in C57/BL nude mice treated with or without PRIMA-1 (100 mg/kg) for 6 d. In FIGURE 4D, the distribution of tumour wet weights after 4 weeks of melanoma tumour formation with or without PRIMA-1 treatment as described in Fig. 4C are displayed.

Detailed description of the invention

p53 is mutated in most human tumours, but the rare p53-mutation frequency in malignant melanoma is puzzling. However, malignant melanoma express high levels of integrin $\alpha_v\beta_3$, an integrin that promotes melanoma cell survival (Montgomery et al., *PNAS* 91: 8856-8860 (1994); Petitclerc et al; 1999; Hsu et al., *Am J Pathol* 153: 1435-1442 (1998)) and suppresses p53-activity in endothelial cells (Strömbäck et al., *J. Clin. Invest.* 98:426-433 (1996); Strömbäck et al., *J. Biol. Chem.* 277: 13371-13374 (2002)). The present inventors now suggest that integrin $\alpha_v\beta_3$ suppresses melanoma wt p53-activity via induction of a previously unknown inactive, unfolded wt p53-conformation. Said integrin $\alpha_v\beta_3$ -regulated p53-activity has been found to govern melanoma cell survival and tumour growth. Dominant negative p53 (His175) was found to restore cell survival and tumor growth of melanoma cells lacking integrin $\alpha_v\beta_3$, suggesting that the integrin-mediated inactivation of p53 controls melanoma cell survival. The compound 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one, also referred to as PRIMA-1, previously known from WO0224692 to have the ability to revert mutant p53-conformation to an active state, surprisingly restored the active conformation of wt p53 in melanoma cells, induced apoptosis and blocked melanoma tumor growth in a wt p53-dependent manner. These results may explain the lack of need for p53-mutations in malignant melanoma, and points to a novel principle for melanoma therapy.

Strömbäck, S. et al. in *J. Clin. Invest.* 98:426-433 (1996), cited above, the contents of which is incorporated in its entirety herein by reference, reported that prolifera-

2003-03-24

Huvudfaxes Kassan

5

tive endothelial cells become apoptotic in response to antagonists of integrin $\alpha_v\beta_3$, leading to the regression of angiogenic blood vessels, and thereby blocking the growth of various human tumours, and that the blocking of integrin $\alpha_v\beta_3$ lead to activation of p53.

5

Based on the findings reported in the above paper, and the findings disclosed in the present application, the inventors also believe the present compounds to be capable of inducing apoptosis in proliferative endothelial cells during angiogenesis, thereby inducing regression of angiogenic blood vessels and blocking various disease states dependent on blood vessel formation and/or vascular cell survival, including the growth and metastasis of various human tumours; adult blindness, e.g. caused by diabetic retinopathy or macular degeneration; psoriasis; states of chronic inflammation, e.g. rheumatoid arthritis; and hemangioma. Consequently, the same inactive wt p53 conformation as disclosed herein is also believed to be present in such proliferative endothelial cells during angiogenesis.

While the inactive conformation of wt p53 in melanoma cells is believed to be induced by the integrin $\alpha_v\beta_3$, the mechanism underlying the induction of any similar inactive wt p53 states in other tissues could be different. However, since the actual mechanism of action of the present compounds is not fully understood, it is also conceivable that the same compounds could be useful for treating other pathological conditions wherein inactive wt p53 is present.

Substances useful in treating other pathological conditions wherein inactive wt p53 is present can be found by means of the generic method of the present invention.

As used herein, the term "inactive wt p53 conformation" is used interchangeably with the term "inactive, unfolded wt p53 conformation" to designate a conformation of wt p53 which is reactive with the monoclonal antibody Pab 240, but does not react with the monoclonal antibody Pab 1620. Furthermore, the inactive conformation also has the ability of being transformed into an active wt p53 conformation by means of the above chemical compound designated PRIMA-1. Inactive wt p53 conformation is further characterized as being incapable of binding to DNA, and incapable of mediating apoptosis.

2003-03-24

Hovrätten Kärnan

6

Pab 240 has previously only been known to be reactive with mutant p53 under non-denaturing conditions, while being equally reactive with mutant p53 and wt p53 under denaturing conditions. However, the present inventors have now found Pab 240 also to be reactive to the inactive state of wt p53, defined herein, under non-denaturing conditions.

Integrin $\alpha_v\beta_3$ plays a critical role for cutaneous melanoma progression displaying increased expression in the vertically growth phase melanoma lesions compared to more benign radial growth phase lesions (Albeda et al., *Cancer Res.* 50: 6757-6764 (1990)). In experimental models, expression of integrin $\alpha_v\beta_3$ promotes melanoma cell survival, tumour growth and conversion from radial to the vertical growth phase while blocking of integrin $\alpha_v\beta_3$ inhibits melanoma tumour growth by inducing apoptosis (Felding-Habermann, *J Clin Invest.* 89: 2018-22 (1992); Petitclerc et al., 1999; Hsu et al., 1998), implicating that integrin $\alpha_v\beta_3$ functionally regulates melanoma cell survival. Indeed, integrin $\alpha_v\beta_3$ has also been found to promote melanoma cell survival in a 3-dimensional environment *in vitro* (Montgomery et al., 1994). But, it is still unclear how integrin $\alpha_v\beta_3$ can control melanoma cell survival.

The tumour suppressor protein p53 functionally induces apoptotic cell death in response to various types of stresses (Oren, *Cancer Biol.* 5: 221-227 (1994); Ko and Prives, *Genes Dev.* 10: 1054-1072 (1996); Levine, *Cell* 88: 323-331 (1997)). Activated p53 can trigger apoptosis via two pathways (Vousden, *Cell* 103: 691-694 (2000)). One of them is associated with death receptors and activation of caspase-8 (Ashkenazi and Dixit, *Science* 281: 1305-8 (1998)), while the other apoptosis pathway is mediated through mitochondrial cytochrome c release and subsequent activation of Apaf1 and caspase-9 (Green and Reed, *Science* 281: 1309-12 (1998)). Furthermore, p53 acts as a specific DNA binding protein to activate or repress expression of a variety of genes, including transcriptionally activating bax (Miyashita et al., *Cell* 80: 293 (1995)), PIG3 (p53-inducible gene 3, Venot et al., *EMBO J.* 17: 4668-79 (1998)) and PUMA (p53 upregulated modulator of apoptosis, Nakano and Vousden, *Mol Cell.* 7: 683-694 (2001)) and transcriptionally repressing bcl-2 (Zhan et al., *Oncogene* 9: 3743-51 (1994)). These downstream targets are functionally involved in certain p53-mediated apoptotic processes.

A new mechanism for p53-induced apoptosis acting directly on the mitochondrial membrane has recently been reported by Mihara, A. et al. in "p53 has a direct apoptogenic role at the mitochondria", *Molecular Cell*, published, 27 January 2003. In accordance therewith, p53, by moving rapidly to the mitochondria, effectively 'jump starts' and amplifies its slower-starting transcription-dependent effect on apoptosis.

In addition, an antagonist of integrin $\alpha_v\beta_3$ induces proliferative endothelial cell apoptosis, which is associated with activation of p53 (Strömbäck et al., 1996; Strömbäck et al., 2002). Although p53 is mutated in most human tumors, wt p53 is dominant in malignant melanoma (Hollstein et al., 1991; Sparrow et al., 1995; Hartmann et al., 1996). In addition, malignant melanoma are typically refractory to apoptosis induction by chemical drugs or radioactivity.

Experimental

15

In order to demonstrate that integrin $\alpha_v\beta_3$ -mediated regulation of p53 regulates melanoma cell survival, the following experimentation, which will be described in more detail hereinafter, was performed. First, M21 human melanoma cells expressing integrin $\alpha_v\beta_3$, and the M21L subpopulation lacking integrin $\alpha_v\beta_3$, were analyzed in a 3-dimensional collagen model mimicking the pathophysiological dermal environment. It was found that integrin $\alpha_v\beta_3$ inhibited p53 activity by inducing an inactive wt p53 conformation. Furthermore, overexpression of a dominant negative p53 mutant (His175) restored M21L ($\alpha_v\beta_3$ -) cell survival and tumour growth, suggesting that p53 is a key target for integrin $\alpha_v\beta_3$ promoting melanoma cell survival. Importantly, PRIMA-1 could restore the active conformation of wt p53 in M21 cells and thereby induce melanoma cell apoptosis and suppress melanoma tumour growth. These results reveal a novel principle for treatment of melanoma by reactivation of wt p53.

30

Integrin $\alpha_v\beta_3$ promotes melanoma cell survival

With reference to Figure 1A, the maternal human melanoma cells M21, expressing integrin $\alpha_v\beta_3$, and a subpopulation, M21L, lacking integrin $\alpha_v\beta_3$, were cultured in a three-dimensional collagen gel (3D-collagen). At indicated times, apoptosis was detected by FITC-Annexin-V staining. FACS analysis showed that M21L cells lacking

2003-03-24

Huvudfakten Kassen

8

$\alpha_v\beta_3$ became apoptotic to a much higher degree than M21 cells ($\alpha_v\beta_3+$), suggesting that integrin $\alpha_v\beta_3$ expression is critical for melanoma cell survival.

The maternal human melanoma cells M0, lacking integrin $\alpha_v\beta_3$; M0-2baV, M0 cells overexpressing a chimera of the extracellular domain of the integrin IIb subunit with the cytoplasmic tail of the integrin α_V subunit; and M0- α_V cells expressing high levels of the integrin α_V subunit, were cultured in a 3D-collagen. At indicated times, apoptosis was examined by FITC-Annexin-V staining. As shown in Figure 1B, FACS analysis showed that M0 α_V cells (expressing $\alpha_v\beta_3$) survived well while both M0 and M02baV cells underwent apoptosis to a higher degree at all time points. This indicates that the integrin α_V -subunit extracellular ligand binding part is important for melanoma cell survival.

Cell surface expression of integrin $\alpha_v\beta_3$ and the integrin β_3 subunit was analyzed in the human melanoma cell lines M21, M21L, M0, M0- α_V and M0-2baV stained with anti- $\alpha_v\beta_3$ Mab LM609 and anti- β_3 Mab AP3, respectively. As can be seen from Figure 1C, FACS analysis showed that both $\alpha_v\beta_3$ and the β_3 subunit were expressed in all M21 and M0 α_V cells but rarely expressed in M21L and M0 cells. While integrin β_3 was expressed in virtually all M0-2baV cells, integrin $\alpha_v\beta_3$ was not present.

It has been suggested that unligated integrin $\alpha_v\beta_3$ might cause apoptosis by direct induction of caspase-8 cleavage (Stupack et al, *J. Cell Biol.* 155: 459-470 (2001)). Therefore, lysates prepared from M21 and M21L cells out of 3D-collagen after 3, 5 and 7 days were analysed by Western blotting for cleavage of caspase-8 and caspase-9. With reference to Figure 1D, no cleavage of caspase-8 in these melanoma cells was observed, while a control with cycloheximide-treated Jurkate cells displayed caspase-8 cleavage. However, caspase-9 was cleaved to a higher degree in M21L cells ($\alpha_v\beta_3 -$) as compared to M21 ($\alpha_v\beta_3 +$) cells, indicating that lack of integrin $\alpha_v\beta_3$ caused apoptosis in M21L cells and that this apoptosis might be mediated by a mitochondrial apoptotic pathway involving caspase-9 but did not involve any detectable activation of caspase-8.

Integrin $\alpha_v\beta_3$ induces an unfolded conformation of wt p53 and suppresses wt p53 activity

46 8 4291070

Ink. t. Patent- och reg.verket

2003-03-24

9

Huvudskriven Kassan

The specific p53 DNA binding activity was examined in M21 and M21L cells collected from 3D-collagen using an electrophoretic gel shift assay (EMSA) with a p53 supershift using Pab 421. The p53 activity was similar in M21 and M21L cells at day 0. However, as shown in upper panel of Figure 2A, M21L cells lacking integrin $\alpha_v\beta_3$ displayed an increased p53 activity after culturing in 3D-collagen while M21 cells ($\alpha_v\beta_3+$) did not.

The protein levels of p53 were analyzed by Western blotting using anti-p53 Pab. With reference to lower panel of Figure 2A, the p53 protein levels in M21 and M21L cells showed no difference within 7 d in 3D-collagen (examination performed on day 0, 3, 5 and 7). The levels of actin were examined as a loading control. This indicates that integrin $\alpha_v\beta_3$ regulates p53 activity without influencing p53 protein levels.

The specific p53 DNA binding activity was examined in M0 and M0aV cells after incubation within 3D-collagen for 5 and 7 days, respectively. The EMSA assay showed that the p53 activity was higher in M0 cells lacking integrin $\alpha_v\beta_3$ than that in M0aV cells ($\alpha_v\beta_3+$) (see Figure 2B). This verifies the role for integrin $\alpha_v\beta_3$ regulating melanoma cell p53 activation state in a second cell system.

Acetylation of p53 at lysine 382, a known acetylation site for p53 activation was examined by Western blotting using anti-acetylation p53-L382 pab. As can be seen from Fig. 2C, the levels of acetylated p53 were reduced in M21 cells ($\alpha_v\beta_3+$) as compared to M21L cells ($\alpha_v\beta_3-$), while total p53 levels remained the same.

With reference to Figure 2D, the conformation of p53 was analyzed by ELISA using Pab1620 recognizing the active, folded p53 conformation; Pab 240 recognizing an inactive, unfolded p53 conformation and; DO1 recognizing both folded and unfolded p53 conformations. Data shown in Figure 2D represents Pab 1620 and Pab 240 reactivity as percentage of D01 reactivity (total p53). It was found that both M21 cells ($\alpha_v\beta_3+$) and M21L ($\alpha_v\beta_3-$) displayed an active p53 conformation in regular culture. However, p53 switched to an inactive unfolded p53 conformation after incubation in 3D-collagen-incubated M21 cells ($\alpha_v\beta_3+$), while M21L ($\alpha_v\beta_3-$) maintained an active p53 conformation. This suggests that integrin $\alpha_v\beta_3$ regulates wt p53 conformation in melanoma cells in a pathophysiological 3-dimensional environment.

46 8 4291070

Ink t Patent- och reg.verket

2003-03-24

10

Huvudfaxon Kassan

and that the lack of p53-activity in cells expressing integrin $\alpha_v\beta_3$ is caused by an unfolded, inactive p53-conformation.

5 **Integrin $\alpha_v\beta_3$ -regulated p53 controls melanoma cell survival and melanoma tumor growth**

M21L cells ($\alpha_v\beta_3^-$) were stably transfected with a dominant negative p53-His175 and a number of clones, including M21Lp53His175-0, M21Lp53His175-1, M21Lp53His175-8 and M21Lp53His175-32 were identified by examining p53 activity using EMSA after incubation in 3D-collagen for 5 d. The p53 activity in these clones was reduced to a similar level as in M21 cells expressing $\alpha_v\beta_3$ (boxed in Figure 3A). The M21L-p53His175 clones, M21L and M21 cells were incubated within 10 3D-collagen and apoptosis was examined by FITC-Annexin-V staining at times indicated in Figure 3A. FACS analysis showed that the number of apoptotic cells was 15 lower in the M21L carrying dn p53 clones as compared to M21L, and that the rate of apoptosis in the M21L-dnp53 clones was similar to that in M21 cells expressing integrin $\alpha_v\beta_3$, indicating that the over-expression of dominant negative p53 could rescue M21L cells from apoptosis to a similar degree as expression of integrin $\alpha_v\beta_3$ itself.

20

Role of integrin-regulated p53 in melanoma tumour growth was investigated *in vivo*. Results are shown in Figure 3B. Melanoma cells (1×10^6), including M21L, M21 and M21L-dn p53 clones M21Lp53His175-0 and M21Lp53His175-8, were injected s.c. into the back of 6-week-old C57/BL nude mice. Each type of injected cell 25 type included 7 mice. The tumours were allowed to grow for 4 weeks. Tumours were found to be formed by M21Lp53His175-0, M21Lp53His175-8, and M21 cells ($\alpha_v\beta_3^+$), while M21L cells lacking integrin $\alpha_v\beta_3$ typically did not form tumours within this time.

30 Tumour volumes were monitored for melanoma growth, as described in the preceding paragraph. Tumour volume over time was determined by the formula: width² × length × 0,52. With reference to Figure 3C, the displayed values are mean tumour volumes out of 5-7 animals for each tumour cell type. In the Figure, ◆ represents M21; □ M21L; ▲ Lp53His175-0; and ★ Lp53His175-8. M21Lp53His175-0 and 35 M21Lp53His175-8 formed large tumours similar in size to M21 tumours. However,

M21L cells lacking integrin $\alpha_v\beta_3$ typically grew only minimal or developed no tumours.

- Scatter graph showing the distribution of tumour wet weights of M21, M21L,
 5 M21Lp53His175-0 and M21Lp53His175-8 are contained in Figure 3D. Cells were
 grown s.c. in nude mice for 4 weeks as described in Fig 3B.

Example

- 10 In this example it will be demonstrated that PRIMA-1 induces an active p53 conformation in integrin $\alpha_v\beta_3$ positive melanoma cells, promotes melanoma cell apoptosis and suppresses melanoma tumour growth *in vivo*.

PRIMA-1 is a substance known from WO0224692 to be able to reactivate the apoptosis-inducing function of mutant p53 proteins. To test if PRIMA-1 could affect also the unfolded, inactive conformation of wt p53 in melanoma cells enforced by integrin $\alpha_v\beta_3$, M21 cells ($\alpha_v\beta_3^+$) and M21L cells ($\alpha_v\beta_3^-$) were incubated with or without 100 μ M PRIMA-1 in 3D-collagen for 7 d. The p53 conformation was examined as described above. The results are presented in Figure 4A. As can be seen, PRIMA-
 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10100 10105 10110 10115 10120 10125 10130 10135 10140 10145 10150 10155 10160 10165 10170 10175 10180 10185 10190 10195 10200 10205 10210 10215 10220 10225 10230 10235 10240 10245 10250 10255 10260 10265 10270 10275 10280 10285 10290 10295 10300 10305 10310 10315 10320 10325 10330 10335 10340 10345 10350 10355 10360 10365 10370 10375 10380 10385 10390 10395 10400 10405 10410 10415 10420 10425 10430 10435 10440 10445 10450 10455 10460 10465 10470 10475 10480 10485 10490 10495 10500 10505 10510 10515 10520 10525 10530 10535 10540 10545 10550 10555 10560 10565 10570 10575 10580 10585 10590 10595 10600 10605 10610 10615 1

46 8 4291070

Ink. t Patent- och registrerat

2003-03-24

Fluydboxen Kassan

12

mice. The mice were treated with or without PRIMA-1 (100 mg/kg) for 6 d starting 6 d after tumour inoculation. The graph in Figure 4C shows mean tumour volumes calculated as described above for four mice in each group. PRIMA-1 significantly inhibited M21 melanoma growth as compared to PBS control.

5

In Figure 4D, the distribution of tumour wet weights after 4 weeks of melanoma tumour formation with or without PRIMA-1 treatment as described in Fig. 4C are displayed. The finding that PRIMA-1 can suppress tumour growth of melanoma cells carrying wt p53 points to a novel principle for treatment of malignant melanoma by re-activating an inactive conformation of wt p53, which was kept inactive by integrin $\alpha_v\beta_3$.

10

Based on these unexpected findings the present inventors also expect structural analogues of PRIMA-1, such as PRIMA-2 and PRIMA-3, which have been described in WO0224692, as well as further analogues of PRIMA-1 described in International Patent Application No. PCT/SE03/00206 (not published) to exhibit similar activity as PRIMA-1.

20

In the compounds of formula I above, the phenyl group or the nitrogen-containing ring structure of R1, and the benzyloxy group of either of A₁ and A₂ can optionally be substituted, such as for example with halogen, methyl, methoxy, amino and/or halomethyl containing 1-3 halogen atoms.

25

The term halogen or halo refers to a fluorine, chlorine, bromine or iodine atom, of which chlorine generally is preferred. A compound of the invention may be in free form, e.g., amphoteric form, or in salt, e.g., acid addition or anionic salt, form. A compound in free form may be converted into a salt form in an art-known manner and vice-versa.

30

The pharmaceutically acceptable salts of the compounds of formula I (in the form of water, or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts of these compounds, which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, diglu-

35

conate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, paemoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Preferred specific examples of the compounds which can be used according to the present invention are 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one (also referred to as PRIMA-1), 9-(azabicyclo[2.2.2]octan-3-one)-6-chloro-9H-purine (also referred to as PRIMA-2), 2-(hydroxymethyl)quinuclidine-3,3-diol (also referred to as PRIMA-3), 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone, or a pharmaceutically acceptable salt thereof.

30


More preferably, the substance of the present invention has the structure of the following general formula I'

14

Ink. t. Patent- och reg. verket

2003-03-24

Huvudfaxen Kassan



wherein

- 5 one of R₁ and R₂ is hydrogen and the other is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and, more preferably the methylene group is linked to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue.
- 10 More preferably, one of R₁ and R₂ in formula I and I' is hydrogen, or both R₁ and R₂ are hydroxymethyl groups.

The following compounds are believed to exhibit an activity similar or greater than that of PRIMA-1: 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone and 2-(6-methoxypurine-9-methylene)-3-quinuclidinone.

20 General procedure for testing substances for ability of transferring wild type p53 from its inactive conformation into an active conformation

The inventive methods of testing substances are based on detection of wild type p53 in inactive conformation, either in a direct or indirect manner, as will be explained below.

25 In the methods of the present invention it is essential that only wild type and not mutant p53 is present. Accordingly, in any cells used in the method, only wild type p53 should be expressed, i.e. the p53 gene must not be mutated. Expression of wt p53 can readily be determined by the person skilled in the art using any suitable conventional methods, such as sequencing, mass spectroscopy, DNA-binding tests etc.

Naturally, it is also essential that the inactive form of wt p53 is present during testing. The presence of the inactive form of wt p53 can then suitably be established in a direct manner by using Pab240.

- 5 More particularly, the present inventors have found that wt p53 is inactivated under the following conditions: In melanoma cells cultured *in vitro* in a 3-dimensional environment, such as 3D collagen; in melanoma cells in tissue culture after irradiation with UV or gamma radiation, and; in melanoma cells grown *in vivo* in mice. The inventors also predict that wt p53 will take an inactive conformation in angiogenic
10 vascular cells during angiogenesis and that the wt p53 inactive conformation is also present in additional cell types and tissues and in other cases can be induced by other means of treatment.

15 The method of monitoring any changes in the level of inactive wt p53 during testing is not critical according to the invention, as long as the method allows for detection of any substantial reduction in the level inactive wt p53 and a consequent induction of active p53 levels.

20 Based upon the above definition of the new inactive wt p53 state, and the present detailed description, the skilled person will be able to find suitable methods for detecting and/or monitoring the level of inactive wt p53 using common general knowledge. Such methods will generally be based on measurement of wt p53 conformation and/or activity state, as will be explained below in further detail.

25 During testing, the level of inactive wt p53 can for example be established by using a suitable conformational-specific antibody, recognising only the inactive form, such as the above-mentioned Pab240. Since the total cellular level of wt p53 is formed by the combined levels of inactive p53 and active p53, respectively, measurement of the active p53 conformation can also be used as an indirect measurement of inactive p53, i.e. an absence of active p53 indicates that p53 is instead inactive. Measurement of the active p53 conformation can also be performed using a suitable conformational-specific antibody, such as Pab 1620. If desired, the total level of wt p53 can be measured by means of a suitable antibody, which does not discriminate between the inactive and active forms of wt p53, such as DO1.

- Of course, other direct or indirect parameters reflecting the activity state of wt p53 could also be used. Accordingly, the activity state of wt p53 can for example be detected by measurement of p53-bindning to DNA, by absence of expression of reporter constructs, for example using GFP or luciferase as reporters, by measurement of 5 p53 target genes, e.g. PUMA-1, PIG-3, bax, bcl-2 and/or caspase-3, by using microarray-related techniques to analyse specific p53 target genes or gene expression patterns indicating p53 activity and/or by measuring the capability of wt p53 to induce apoptosis and/or growth arrest.
- 10 Also, as indicated in Fig 2C, specific p53 acetylation could also be used as an indication of p53 activity. Likewise, phosphorylation of p53 is also conceivable as an indication of p53 activity.

15 The use of antibodies is however presently preferred for being a practical and more direct method of detecting and monitoring inactive wt p53, especially when Pab240 is used.

20 The general method of testing substances for the ability of transferring wt p53 from an inactive conformation into an active conformation according to the present invention will thus include the following general steps:

- A. Providing cells carrying wt p53 wherein inactive wt p53 conformation is present;
- B. Exposing the cells to a substance to be tested; and
- C. Measuring the cellular level of inactive wt p53 conformation, for example by 25 any of the above-mentioned methods.

The above general method can be adapted to both *in-vitro* or *in-vivo* testing by exposing the cells in step B either *in vivo* or *in vitro* to the substance to be tested, as will be readily understood hereinafter.

30 Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.

35 *In vitro* testing of substances for ability of transferring wild type p53 from its inactive conformation into an active conformation

46 8 4291070

Ink. t Patent- och reg.verket

2003-03-24

Huvudfaxen Kässan

17

In the case of *in-vitro* testing for substances capable of reverting an inactive p53 conformation to an active conformation, cells carrying wt p53 can be grown in a 3-dimensional environment and the conformation and/or activity state of p53 measured, for example by any of the methods mentioned above, with and without, respectively, the addition of a substance for testing. A substance is considered functional if it is found to be capable of changing the conformation and/or activity of inactive wt p53. Alternatively, cells with wt p53 could be irradiated in order to induce the inactive wt p53 conformation, exposed to a substance to be tested, and thereafter analysed for p53 conformation and/or activity. Alternatively, a cell naturally displaying an inactive wt p53 conformation could be utilized or an inactive wt p53 conformation could be induced by other means, the cell thereafter being exposed to a substance to be tested, and analysed for inactive p53 state.

15 A tissue, an organ, or a part thereof, from a human or from an animal could also be cultured, treated and used for the inventive testing as described for cells *in vitro* above. Although such models sometimes are referred to as *ex-vivo* models, when used in the inventive method of testing of substances herein, such method is considered to be a method of *in-vitro* testing.

20

Alternatively, *in-vitro* testing of substances could be performed in models of angiogenesis. In vitro examples include, but are not limited to, tube forming assays of endothelial cells, outgrowth of blood vessels from stem cells, outgrowth of blood vessels from an isolated vessel originating from an animal or human, or analysis of 25 endothelial cells in tissue culture.

An *in-vitro* testing procedure could thus for example include the following general steps:

- A. Providing cells carrying wt p53 *in vitro*, and inducing inactive wt p53 conformation if not already present;
- 30 B. Exposing the cells to a substance to be tested; and
- C. Measuring the cellular level of inactive wt p53 conformation, directly or indirectly for example by any of the above-mentioned methods.

2003-03-24

Huvudforsen Kassan

18

Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.

5 ***In vivo testing of substances for ability of transferring wild type p53 from its inactive conformation into an active conformation***

Likewise, wt p53 conformation and/or activity could be assessed *in vivo*. For example, melanoma cells xenografts could be used *in vivo* to test substances for their capacity of reverting an inactive p53 conformation to active p53. In this case, an animal carrying such tumour xenograft would be treated with a substance to be tested, and the effect of this substance on wt p53 conformation and activity measured as described above. Alternatively, testing of substances could be carried out in animal melanoma models, where melanoma is occurring naturally or is provoked within the animal by treatment e.g. by UV-radiation and/or by carcinogenic chemicals and/or by genetic modifications. Administration of test substance to animal can be performed i.v., i.p., s.c., intratumoural, or otherwise.

20 Alternatively, *in-vivo* testing of substances could be performed in models of angiogenesis. Examples of *in-vivo* models include, but are not limited to, stimulation of angiogenesis in the chick embryo chorioallantoic membrane, stimulation of angiogenesis by a transplant of extracellular matrix or comparable substances onto mice or onto another animal, stimulation of angiogenesis in the cornea by an angiogenic compound, stimulation of angiogenesis in the retina by hypoxia, analysis of developmental angiogenesis in the retina or elsewhere, and induction of angiogenesis by a tumour xenograft or another type of xenograft. Measurement of angiogenesis is performed by a quantification of the number of blood vessels within the tissue and/or by quantification of vascular cell markers and/or by measurement of vascular cell apoptosis and/or by similar means.

30 An *in-vivo* testing procedure could for example comprise the following general steps:

- A. Providing an animal expressing wt p53 in a tissue thereof, wherein inactive wt p53 conformation is present;
- B. Exposing cells of the tissue of the animal *in vivo* to a substance to be tested; and

46 8 4291070

Ink. t. Patent- och reg.verket

2003-03-24

19

Huvudfaxen Kässan

C. Measuring the cellular level of inactive wt p53 conformation, directly or indirectly, for example by any of the above-mentioned methods.

Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.

The animals are typically sacrificed after the above-described *in-vivo* testing of substances.

10
09
08
07
06
05
04
03
02
01

46 8 4291070

20


Ink t Patent- och reg.verket

2003 -03- 2 4

Huvudfaxon Kassan

Claims

1. Use of a compound capable of transferring wild type p53 from an inactive conformation thereof, which conformation is reactive to Pab 240 and not to Pab 1620, 5 into an active conformation capable of inducing apoptosis, which compound is selected from compounds having a structure according to the formula I.




10 wherein:

R₁ and R₂ are independently selected from hydrogen, hydroxymethyl, or a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, or R₁ and R₂ may together represent a double bonded methylene group, and;

- 15 A₁ and A₂ are independently selected from hydrogen, hydroxyl, and benzyloxy, or A₁ and A₂ may together represent an oxygen atom being double bonded, with the proviso that when either of A₁ and A₂ is a benzyloxy group, both R₁ and R₂ are hydrogen,
- 20 or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for use in treating medical conditions wherein wt p53 is inactive.

2. The use of claim 1, wherein the compound is selected from compounds having the structure of the general formula I'

25



wherein

46 8 4291070

Ink t. Patent- och registreringsverket

2003-03-24

21

Huvudfaxon Kesson


one of R₁ and R₂ is hydrogen and the other is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and, more preferably the methylene group is linked to a nitrogen atom contained in the 5 ring structure of a purine, 8-azapurine, or benzimidazol residue.

3. The use of claim 1, wherein the compound is selected from 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one, 9-(azabicyclo[2.2.2]octan-3-one)-6-chloro-9H-purine, 2-(hydroxymethyl)quinuclidine-3,3-diol, 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone, or a pharmaceutically acceptable salt thereof.

4. The use of anyone of the claims 1-3 together with a pharmaceutically acceptable carrier, diluent and/or excipient.

5. The use of any of the previous claims, wherein the medical condition is malignant melanoma and/or a pathological condition involving undesired angiogenesis.

25 6. A method of treating malignant melanoma and/or inhibiting undesired angiogenesis, comprising administrating to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I



(I)

2003-03-24

22

Huvudfaren Kassan

wherein:

R₁ and R₂ are independently selected from hydrogen, hydroxymethyl, or a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, or R₁ and R₂ may together represent a double bonded methylene group, and;

A₁ and A₂ are independently selected from hydrogen, hydroxyl, and benzoxyloxy, or A₁ and A₂ may together represent an oxygen atom being double bonded, with the proviso that when either of A₁ and A₂ is a benzoxyloxy group, both R₁ and R₂ are hydrogen.

7. Method of testing compounds for the ability of transferring wild type p53 from an inactive conformation into an active conformation comprising the steps:

A. Providing cells carrying wt p53, in which cells inactive wt p53 conformation is present;

B. Exposing the cells to a substance to be tested; and

C. Measuring the cellular inactive wt p53 conformation.

8. The method of claim 7, wherein integrin α_vβ₃ is present in the cells.

20

9. The method of claim 7 or 8, wherein the Pab 240 is used for detecting wt p53 in its inactive conformation.

10. The method of any of the claims 7-9, wherein a compound of claim 1 is tested.

25

11. The method of any of the claims 7-10, wherein the cells in step B are exposed in vivo to the substance to be tested.

46 8 4291070

Ink. t. Patent- och reg.verket

2003-03-24

Huvudfaxon Klassen

ABSTRACT

The present invention relates to the use of certain compounds, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical composition for use in treating medical conditions wherein wt p53 exists in an inactive state defined herein, and especially malignant melanoma. The invention also relates to methods of *in vivo* and *in vitro* testing of compounds for the above-mentioned ability, wherein inactive wt p53 is monitored or detected.

10
9
8
7
6
5
4
3
2
1

46 8 4291070

1/11

Ink. t Patent- och reg.v.
2003-03-24
Huvudfaxen Kassar

Figure 1A





Figure 1B



46 8 4291070


2/11

Figure 1C

Ink. t. Patent- och reg.verket

2003-03-24

Huvudfaxen Kassan



46 8 4291070

3/11

Figure ID

Ink. t. Patent- och reg.yrket

2003-03-24

ମୁଖର୍ଜୀଙ୍କ କବିତା





Figure 2A



03 03/24 16:49 FAX 46 8 4291070

BRANN I ATTENTBYRA AB


→ PRV

030

46 8 4291070

4/11

Figure 2B



03 03/24 16:49 FAX 46 8 4291070

BRANN PATENTBYRA AB

→ PRV

031

46 8 4291070

5/11

Figure 2C


Figure 2

Ink t Patent- och reg.verket

2003 -03- 2 4

Huvudfaxes Kassan

D





46 8 4291070

6/11

Figure 2D

Ink t Patent- och reg.verket
2003-03-24
Hurudfacken Kassan





46 8 4291070

7/11

Figure 3A

Ink t Patent- och reg.verk
2003-03-24
Huvudfaxon Kossan



46 8 4291070

8/11

Ink t Patent- och PT-verket
2003-03-24
Huvudfaxen Kassan

Figure 3B





Figure 3C



46 8 4291070

9/11

Ink t Patent- och reg.verket

2003-03-24

Huvudfaxen Kassan

Figure 3D






Figure 4A



46 8 4291070


10/11

Figure 4B



Ink t Patent- och reg.verket
2003-03-24
Huvudfaxen Kassan


Figure 4C



46 8 4291070

11/11

Figure 4D



Ink t Patent- och reg.ver
2003-03-24
Huvudfaxen Kassan

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.